What's in the pipeline?

Come and find out what we have in the pipeline and explore those indications where our technology is set to have the greatest clinical benefit.

Indication
Short Description
Pre-clinical discovery
Pre-clinical development
Phase I/IIa
Phase IIb
Phase III
Status
Active ingredient
Mechanism

Recessive dystrophic epidermolysis bullosa (RDEB) a b d

Genetic disorder with systemic inflammation and severe wounds, reduced life expectancy

In set up

allo-APZ2 1

Anti-inflammation

Non-healing chronic venous wounds (CVU) 4 5

Non-healing wound from venous insufficiency

Recruiting

allo-APZ2 1

Anti-inflammation

Non-healing diabetic foot ulcers (DFU)

Non-healing wound as diabetic complication

In set up

allo-APZ2 1

Anti-inflammation

Limbal stem cell deficiency (LSCD) a b c

A lack of LSCs leading to LSCD, potential blindness

On hold

LSC2 3

Regeneration

Acute graft-versus-host disease (GvHD)

Severe immune response caused by bone-marrow transplant, potential fatal

Ongoing

allo-APZ2 1

Anti-inflammation

Polycystic kidney disease (PKD)

Genetic disorder resulting in renal failure with potential fatal outcome

Ongoing

allo-APZ2 1

Anti-inflammation and Regeneration

Transplant rejection

Complication caused by immune-system overreaction

Ongoing

allo-APZ2 1

Anti-inflammation

Non-healing chronic venous wounds (CVU)

Non-healing wound from venous insufficiency

Closed

APZ2 2

Anti-inflammation



1 Allogeneic ABCB5-positive mesenchymal stem cells
2 Autologous ABCB5-positive mesenchymal stem cells
3 Allogeneic ABCB5-positive limbal stem cells
4 Marketing authorization in Germany granted for AMESANAR®
5 RHEACELL's cell therapy product AMESANAR® is now listed on the website of Germany's Federal Institute for Vaccines and Biomedicines (competent authority)

a Orphan Drug Designation FDA
b Orphan Drug Designation EMA
c Fast Track Designation FDA
d Pediatric Investigation Plan (PIP) approved by PDCO (EMA)

© 2022 RHEACELL. All rights reserved.